Depo-Provera, the popular injectable birth control shot, has helped millions of women prevent pregnancy for decades. However, as of January 2026, growing evidence links long-term use to an increased risk of meningioma—a type of brain tumor. Thousands of women have filed claims against Pfizer (the manufacturer), alleging the company failed to adequately warn about this potential danger. With over 1,750 cases now consolidated in federal multidistrict litigation (MDL) and the first bellwether trial set for late 2026, the Depo-Provera lawsuit 2026 is advancing rapidly. This post outlines the latest developments so affected women can better understand their situation and next steps.
Background on Depo-Provera and Meningioma Risks
Depo-Provera (medroxyprogesterone acetate) is administered every three months to suppress ovulation. Studies, including a major 2024 French analysis, have shown that prolonged use (especially over one year) can increase meningioma risk up to 5.5 times due to the drug’s progestin effects on tumor growth. Meningiomas are often benign but can cause serious symptoms like headaches, vision issues, seizures, or require surgery/radiation.
Plaintiffs claim Pfizer knew or should have known about these risks from earlier research but did not provide sufficient warnings on labels. While Pfizer maintains the drug is safe when used as directed, the FDA approved a label update in December 2025 to include meningioma information: “Cases of meningiomas have been reported… primarily with long-term use. Monitor… Discontinue if a meningioma is diagnosed.”
Key Depo-Provera Lawsuit Updates in 2026
The litigation (MDL 3140 in the Northern District of Florida, Judge M. Casey Rodgers) is gaining momentum:
- Case Volume Growth — As of early January 2026, there are approximately 1,752 pending cases in the MDL (with totals around 1,775 including resolved/closed). This reflects a sharp rise—hundreds added monthly—driven by awareness of the meningioma link and the FDA’s label change.
- MDL Proceedings — Consolidated in February 2025, the MDL handles coordinated discovery and pretrial matters. Recent orders include expert witness deadlines and status conferences. No global settlement has been announced, but the structure sets up bellwether trials to test key issues.
- Bellwether Trial Schedule — In late 2025/early 2026, Judge Rodgers set the first pilot/bellwether trial for December 2026, with others potentially in early 2027. These will help gauge jury responses and influence future resolutions.
- FDA Label Update Impact — The December 2025 addition of meningioma warnings strengthens plaintiffs’ arguments that earlier failures to warn caused harm. It may limit Pfizer’s preemption defenses and encourage more filings.
- Other Developments — Ongoing discovery focuses on proof of use, injury causation, and Pfizer’s knowledge. Some cases involve recurrent tumors or multiple surgeries linked to long-term injections.
These updates indicate the Depo-Provera lawsuit 2026 remains active and expanding, with trials on the horizon.
What This Means for Potential Claimants
If you’ve used Depo-Provera (especially long-term) and been diagnosed with a meningioma brain tumor, you may qualify for a claim. Courts evaluate:
- Duration and frequency of injections (often 1+ years)
- Medical evidence linking to meningioma (diagnosis, imaging, treatment records)
- Lack of adequate warnings leading to uninformed use
- Resulting harms (surgery, radiation, neurological effects, emotional/financial burdens)
Many claims succeed even without “extreme” use—standard contraceptive dosing has been implicated. Statutes of limitations vary by state (often 2–4 years from diagnosis or discovery), so timely action is key.
Next Steps If You May Have a Claim
- Gather Records — Collect injection dates, medical history, diagnosis reports, and treatment details.
- Document Impact — Note symptoms, procedures, lost wages, or quality-of-life changes.
- Seek Professional Review — Mass tort cases are usually contingency-based—no upfront costs.
With bellwether trials approaching in late 2026, the litigation could lead to settlements or resolutions, but preserving your rights requires prompt steps.
Diagnosed with a meningioma brain tumor after using Depo-Provera? Submit your confidential information today for a free, no-obligation review from our team. We’re here to help answer questions and guide you through the process.
